News | August 17, 2025
Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Subscribe To Our Newsletter & Stay Updated
